The retinoblastoma protein (pRB) can promote HR and NHEJ [30–32], RB1 loss is linked to increased DNA damage [33–36], and the combination of HR gene and RB1 mutations is beneficial in ovarian cancer [37], but whether directly targeting these repair processes could enhance RB treatment is unclear. This evidence concerns the gene RB1 and ovarian carcinoma.